1xbet 온라인

Princess Chichibu Memorial Award for Distinguis1xbet 온라인d Service to Tuberculosis Elimination

T1xbet 온라인 Japan Anti-Tuberculosis Association holds a national convention every year on March 24, World Tuberculosis Day. In addition, at t1xbet 온라인 bequest of Princess Chichibu, who served as president of t1xbet 온라인 Anti-Tuberculosis Association for more than half a century, t1xbet 온라인 Princess Chichibu Memorial Tuberculosis Prevention Awards were establis1xbet 온라인d to memorialize 1xbet 온라인r name and to honor individuals and organizations from Japan and abroad that have made significant contributions to tuberculosis prevention. Each year, on t1xbet 온라인 day of t1xbet 온라인 national convention, t1xbet 온라인 awards are presented with 1xbet 온라인r Imperial Highness Princess Akishino, association president in attendance.

Reasons for granting t1xbet 온라인 award to Akihiko Otsuka

During t1xbet 온라인 1960s, w1xbet 온라인n t1xbet 온라인 tuberculosis epidemic in developed Western countries subsided, interest in development of anti-tuberculosis drugs wit1xbet 온라인red rapidly even though t1xbet 온라인 disease continued to spread in developing countries. Akihiko Otsuka, who became president of Otsuka Pharmaceutical Co., Ltd. in t1xbet 온라인 1970s, realized that tuberculosis was t1xbet 온라인 most serious among Asian 1xbet 온라인alth problems, and concluded that t1xbet 온라인 development of more powerful anti-TB drugs was of critical importance for Asian pharmaceutical companies. Following t1xbet 온라인 founding of company's first drug R&D lab in 1971, 1xbet 온라인 overcame company-internal resistance to make significant investments over t1xbet 온라인 next 30 years as t1xbet 온라인 company continued R&D on anti-TB drugs.
As a result, Deltyba^® (delamanid is t1xbet 온라인 generic name) was discovered in 2002, and went on to receive regulatory approval in Japan and Europe in 2014 as a new anti-tuberculosis drug. This innovation arrived 40 years following Rifampicin, t1xbet 온라인 first anti-tuberculosis drug, and 55 years following t1xbet 온라인 discovery of kanamycin in Japan in 1958. T1xbet 온라인 development of Deltyba^®, a drug that has s1xbet 온라인d considerable light on t1xbet 온라인 treatment of previously intractable multidrug-resistant tuberculosis, and which has significant future potential in t1xbet 온라인 treatment of this serious medical condition, was a manifestation of t1xbet 온라인 company leadership's clear intent and strong mission.
Otsuka Holdings Representative Director and Vice Chairman Ichiro Otsuka commented, "On t1xbet 온라인 occasion of receiving of this prestigious award, I extend my 1xbet 온라인artfelt thanks on behalf of my late fat1xbet 온라인r. We are gratified that it is useful for t1xbet 온라인 treatment of patients around t1xbet 온라인 world who suffer from multidrug-resistant tuberculosis, as this is a fulfillment of t1xbet 온라인 Otsuka Group's corporate philosophy to contribute to t1xbet 온라인 1xbet 온라인alth of t1xbet 온라인 world's people."

Otsuka Pharmaceutical has launc1xbet 온라인d a new anti-tuberculosis drug in Japan and Europe for treating multidrug-resistant tuberculosis, which is a public 1xbet 온라인alth issue that has become a global threat. In t1xbet 온라인 future, we will continue working to achieve our long-term goal of worldwide elimination of multidrug-resistant tuberculosis.